Fremanezumab Lowers Migraine Burden In Pediatric Trial

A recent paper describes a 3-month randomized, placebo-controlled episodic migraine trial in children and adolescents in which fremanezumab was associated with greater reductions in monthly migraine days and in days with at least moderate headache severity than placebo. Participants were 6 to 17 years of age, had a migraine history of at least 6 months, and met eligibility criteria that included no more than 14 headache days per month, consistent with an episodic range. Participants were randomized to fremanezumab or matched placebo and followed for 3 months.

Investigators assigned monthly subcutaneous fremanezumab by body weight (120 mg below 45 kg and 225 mg at 45 kg or more). Participants could use migraine-specific medications for acute headaches during the study period. Change from baseline in monthly migraine days was −2.5 with fremanezumab and −1.4 with placebo, for a between-group difference of 1.1 days (P = 0.02), which the abstract reports as the primary endpoint comparison.

Days per month with headache of at least moderate severity declined by 2.6 with fremanezumab and by 1.5 with placebo. The study also reports that 47.2% of participants receiving fremanezumab achieved at least a 50% reduction in monthly migraine days, compared with 27.0% with placebo (P = 0.002). These outcomes added reported measures of headache severity and responder frequency alongside the primary endpoint.

Injection-site erythema was the most common adverse event, occurring in 9.8% of participants receiving fremanezumab and 5.4% receiving placebo. The authors stated that longer follow-up is needed to better understand efficacy and safety in this population, framing these findings within a brief observation window.

Overall, the paper reports that monthly fremanezumab in eligible children and adolescents was associated with fewer migraine days and fewer days with at least moderate headache severity than placebo. The responder analysis and short-term adverse-event pattern were described in the same direction, while the authors noted that longer follow-up remains necessary.

Key Takeaways

• In this randomized 3-month pediatric episodic migraine trial, fremanezumab was associated with a greater reduction from baseline in monthly migraine days than placebo (between-group difference, 1.1 days; P = 0.02).
• Lower headache-frequency measures and a higher 50% responder rate were also reported among participants receiving fremanezumab.
• Injection-site erythema was the most common adverse event, and the authors concluded that longer follow-up is needed to further clarify efficacy and safety.